-
2023-03-14
Bentrio™鼻喷剂 活力上线 亮相中国香港！
优锐医药亚太区域首款商业产品，Bentrio™鼻喷剂已在中国香港首发上市！
-
2023-03-03
Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties
Altamira Therapeutics Ltd. reported that data from a recent peer-reviewed clinical study involving Bentrio nasal spray's residence time and other rheological properties demonstrated superiority vs. a saline control.
-
2023-02-14
Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meeting
Altamira Therapeutics Ltd. announced that data from three clinical studies with the Company's Bentrio nasal spray in allergic rhinitis will be presented February 25, at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI)
-
2023-01-24
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
Altamira Therapeutics Ltd. provided an update on the clinical trials with Bentrio® in seasonal allergic rhinitis (SAR)
-
2022-12-20
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
Verona Pharma plc (Nasdaq: VRNA) announces positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
-
2022-11-28
优锐医药与大昌华嘉合作在中国香港澳门上市发售Bentrio™鼻喷剂
优锐医药宣布与大昌华嘉（DKSH）医疗保健事业部达成合作，在中国香港、中国澳门上市发售BentrioTM鼻喷剂，标志着优锐医药在亚太区域的商业化权益实质性落地的首个里程碑。
-
2022-11-04
优锐医药首席运营官陈晨 对话蔻德 - 新浪《蕊智会》
优锐医药首席运营官陈晨博士受邀参与由新浪健康主办的《蕊智会》- 蔻德联合高端访谈，深度探讨中国罕见病领域的发展历程、解决路径与前景展望。
-
2022-10-28
专访优锐医药：呼吸精品特药领域，如何打造现金“造血”教科书？
近日，动脉新医药访谈了优锐医药创始人兼CEO Mark Lotter先生。Mark Lotter曾是阿斯利康的首批来华高管，拥有超过20年的中国医疗行业市场经验。Mark Lotter与我们分享了优锐医药如何练就现金“造血”能力，并逐步成长为具有差异化的特药医疗公司。
Contact PR
